Shengfang Jin

Shengfang Jin is a co-founder and the President and CEO of Ensem Therapeutics, a Waltham, Massachusetts biotech developing small-molecule cancer drugs by targeting protein pockets that only exist while the protein is in motion. Under Jin, Ensem built its Kinetic Ensemble platform, took its first CDK2 inhibitor into the clinic, and its ETX-636 breast cancer program earned FDA Fast Track designation. She trained at Tufts and Harvard, spent years at Agios helping deliver first-in-class cancer metabolism drugs, and then ran discovery biology at Editas before starting Ensem.